Apriori Bio Receives $1.1M Funding from CEPI to Advance AI Platform for Virus Protection
Apriori Bio, a pioneering biotechnology firm, has secured a significant funding injection of US $1.1 million from CEPI (Coalition for Epidemic Preparedness Innovations) to propel its cutting-edge artificial intelligence platform, Octavia™. Designed to safeguard against rapidly-evolving viral threats, Octavia™ employs advanced machine learning to predict and counteract virus mutations, crucial for developing variant-resilient vaccines. Octavia™…